The company’s performance highlights a shift toward refined product portfolios, particularly within its peripheral vascular business, which generated RMB400.7 million. This segment saw a 2.3% year-on-year increase, bolstered by strong demand for stent grafts and vena cava filters. Meanwhile, the structural heart disease division contributed RMB200.1 million to the Group’s total revenue. Mainland China remains the primary revenue driver, accounting for 69.6% of total sales, though overseas business grew by 4.1% over the same period.

Investment in innovation remains a priority, with approximately RMB167.1 million allocated to research and development during the first half of the year. This capital supported several regulatory milestones, including NMPA certification for the G-iliac Pro system and multiple CE MDR approvals for its PFO occluders and steerable introducers. As of June 30, 2026, the Group holds 1,370 valid patents, reinforcing its competitive stance as it pursues registration for advanced aortic and peripheral scaffold systems in both Chinese and European markets. Chairman and CEO Xie Yuehui noted that the company continues to prioritize its dual strategy of innovation and internationalization to maintain resilience against global industry volatility.